Beyond Belatacept: Praise and Progress for the FDA

摘要

Transparency and dialogue will be required by the FDA, industry and the transplant community in order to achieve successful clinical trials with novel agents for the challenging unmet needs in organ transplantation. See special article by Archdeacon et al on page 554, and related article by Medina Pestana et al on page 630.